{'fraction_non_alphanumeric': 0.02383053839364519, 'fraction_numerical': 0.00353045013239188, 'mean_word_length': 5.872727272727273, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Variation of activated partial thromboplastin time according to age and sex in a large population study: analytical and clinical implications.

Levetiracetam, a pyrolidine-derivate analogous to piracetam is a new antiepileptic drug reported to have a high degree of tolerability in both adults and children with epilepsy. It is approved in Europe for monotherapy and adjunctive treatment of partial seizures with or without secondary generalization, as well as for adjunctive therapy of myoclonic seizures and primarily generalized tonic-clonic seizures [1]. Common adverse events of levetiracetam include somnolence, agitation, asthenia, headache, abnormal behaviour, depression, mood disorder and suicidal intent. Hematologic adverse effects are extraordinary. Lafora disease is the most common and severe form of adolescent-onset progressive myoclonus epilepsies a group of devastating inherited neurodegenerative disorders characterized by progressively worsening myoclonus, epilepsy, early dementia and death [2]. We present a case of pancytopenia most likely induced by levetiracetam in a 16-years-old girl with Lafora disease.